Jian-Xin Lin

Jian-Xin Lin

Auto-generated profile, based on publicly available information

Jian-Xin Lin

Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Immunity
Verified
Journal Article
Closed access
WLWei Liao
Wei Liao
JLJian-Xin Lin
Jian-Xin Lin
WLWarren J. Leonard
Warren J. Leonard

12 January 2010 in Genome Biology
Verified
Journal Article
Open access
PDF file
KKKumaran Kandasamy
Kumaran Kandasamy
SMS Sujatha Mohan
S Sujatha Mohan
RRRajesh Raju
Rajesh Raju
SKShivakumar Keerthikumar
Shivakumar Keerthikumar
GKGhantasala S Sameer Kumar
Ghantasala S Sameer Kumar
APAkhilesh Pandey
Akhilesh Pandey
We have developed NetPath as a resource of curated human signaling pathways. As an initial step, NetPath provides detailed maps of a number of immune signaling pathways, which include approximately 1,600 reactions annotated from the literature and more than 2,800 instances of transcriptionally regulated genes - all linked to over 5,500 published articles. We anticipate NetPath to become a consolidated resource for human signaling pathways that should enable systems biology approaches.

1 April 2019 in Immunity
Verified
Journal Article
Closed access
WLWarren J. Leonard
Warren J. Leonard
JLJian-Xin Lin
Jian-Xin Lin
JOJohn J. O'SHea
John J. O'SHea

16 October 2017 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Closed access
PDF file
JLJian-Xin Lin
Jian-Xin Lin
WLWarren J. Leonard
Warren J. Leonard
Interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21 form a family of cytokines based on their sharing the common cytokine receptor γ chain (γc), which was originally discovered as the third receptor component of the IL-2 receptor, IL-2Rγ. The IL2RG gene is located on the X chromosome and is mutated in humans with X-linked severe combined immunodeficiency (XSCID). The breadth of the defects in XSCID could not be explained solely by defects in IL-2 signaling, and it is now clear that γc is a shared receptor component of the six cytokines noted above, making XSCID a disease of defective cytokine signaling. Janus kinase (JAK)3 associates with γc, and JAK3-deficient SCID phenocopies XSCID, findings that served to stimulate the development of JAK3 inhibitors as immunosuppressants. γc family cytokines collectively control broad aspects of lymphocyte development, growth, differentiation, and survival, and these cytokines are clinically important, related to allergic and autoimmune diseases and cancer as well as immunodeficiency. In this review, we discuss the actions of these cytokines, their critical biological roles and signaling pathways, focusing mainly on JAK/STAT (signal transducers and activators of transcription) signaling, and how this information is now being used in clinical therapeutic efforts.

26 April 2019 in Annual Review of Immunology
Verified
Journal Article
Closed access
JLJian-Xin Lin
Jian-Xin Lin
WLWarren J. Leonard
Warren J. Leonard
Cytokines are secreted or otherwise released polypeptide factors that exert autocrine and/or paracrine actions, with most cytokines acting in the immune and/or hematopoietic system. They are typically pleiotropic, controlling development, cell growth, survival, and/or differentiation. Correspondingly, cytokines are clinically important, and augmenting or attenuating cytokine signals can have deleterious or therapeutic effects. Besides physiological fine-tuning of cytokine signals, altering the nature or potency of the signal can be important in pathophysiological responses and can also provide novel therapeutic approaches. Here, we give an overview of cytokines, their signaling and actions, and the physiological mechanisms and pharmacologic strategies to fine-tune their actions. In particular, the differential utilization of STAT proteins by a single cytokine or by different cytokines and STAT dimerization versus tetramerization are physiological mechanisms of fine-tuning, whereas anticytokine and anticytokine receptor antibodies and cytokines with altered activities, including cytokine superagonists, partial agonists, and antagonists, represent new ways of fine-tuning cytokine signals.

14 May 2025 in Nature
Verified
Journal Article
Open access
PDF file
JZJiajia Zhou
Jiajia Zhou
KTKole Tison
Kole Tison
HZHaibin Zhou
Haibin Zhou
LBLongchuan Bai
Longchuan Bai
RARanjan Kumar Acharyya
Ranjan Kumar Acharyya
WZWeiping Zou
Weiping Zou
Immune checkpoint blockade (ICB) has transformed cancer therapy1,2. The efficacy of immunotherapy depends on dendritic cell-mediated tumour antigen presentation, T cell priming and activation3,4. However, the relationship between the key transcription factors in dendritic cells and ICB efficacy remains unknown. Here we found that ICB reprograms the interplay between the STAT3 and STAT5 transcriptional pathways in dendritic cells, thereby activating T cell immunity and enabling ICB efficacy. Mechanistically, STAT3 restrained the JAK2 and STAT5 transcriptional pathway, determining the fate of dendritic cell function. As STAT3 is often activated in the tumour microenvironment5, we developed two distinct PROTAC (proteolysis-targeting chimera) degraders of STAT3, SD-36 and SD-2301. STAT3 degraders effectively degraded STAT3 in dendritic cells and reprogrammed the dendritic cell–transcriptional network towards immunogenicity. Furthermore, STAT3 degrader monotherapy was efficacious in treatment of advanced tumours and ICB-resistant tumours without toxicity in mice. Thus, the crosstalk between STAT3 and STAT5 transcriptional pathways determines the dendritic cell phenotype in the tumour microenvironment and STAT3 degraders hold promise for cancer immunotherapy.